LAVA Therapeutics N.V.
LAVA Therapeutics N.V. is a public limited liability company (naamloze vennootschap) registered in the Netherlands under Chamber of Commerce (KvK) number 65335740. Incorporated on 15 February 2016, the company was registered at Yalelaan 62, 3584 CM, Utrecht, and is recorded as inactive on the KvK register following a statutory merger completed in November 2025. Prior to that merger, LAVA Therapeutics N.V. traded on Nasdaq under the ticker LVTX.
LAVA Therapeutics N.V. was a clinical-stage immuno-oncology company that developed bispecific gamma-delta (Vδ2) T-cell engaging antibodies through its proprietary Gammabody platform, aimed at treating solid tumours and blood cancers. Its pipeline included partnered programmes with Johnson & Johnson and Pfizer alongside internally developed candidates such as LAVA-1266. In 2025 the company announced a pipeline reprioritisation to focus on LAVA-1266 while continuing to support its partnered assets.
On 3 August 2025, LAVA Therapeutics N.V. entered into a transaction agreement with XOMA Royalty Corporation, a Nevada corporation listed on Nasdaq under the ticker XOMA, under which XOMA Royalty agreed to acquire all outstanding LAVA shares for between USD 1.16 and USD 1.24 per share in cash, plus a non-transferable contingent value right tied to future proceeds from LAVA’s partnered and unpartnered programmes. Following a tender offer in which approximately 91.1% of shares were validly tendered, LAVA Therapeutics N.V., as the disappearing company, merged into LAVA Therapeutics New Topco B.V. under Sections 2:309 et seq. of the Dutch Civil Code. XOMA Royalty announced completion of the transaction on 21 November 2025, confirming it had acquired 100% of the shares of LAVA’s successor entity; LAVA’s shares were subsequently suspended from trading and delisted from Nasdaq.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of LAVA Therapeutics N.V.
While LAVA Therapeutics N.V. was listed on Nasdaq under ticker LVTX, its share register reflected public market trading and periodic block-holder disclosures rather than a small, fixed group of principal owners; company records on file separately show historical holdings attributed to entities including Shay Capital LLC, Citadel Advisors LLC, Rangeley Capital LLC, GTS Securities LLC and Royal Bank of Canada, but these predate the transaction described below and no longer reflect the company’s current ownership. On 3 August 2025, LAVA Therapeutics N.V. and XOMA Royalty Corporation (Nasdaq: XOMA) entered into a transaction agreement under which XOMA Royalty would acquire all outstanding LAVA shares. Following a tender offer that closed on 20 November 2025 with approximately 91.1% of outstanding shares (23,956,708 shares) validly tendered, LAVA Therapeutics N.V. merged into LAVA Therapeutics New Topco B.V. under a Dutch statutory merger, with XOMA Royalty Corporation announcing on 21 November 2025 that it had acquired 100% of the shares of LAVA’s successor entity. As of that date, XOMA Royalty Corporation is the sole shareholder of LAVA’s successor entity.
Data availability
Classification: Full for current ownership, which is confirmed by XOMA Royalty Corporation’s official closing announcement and SEC filings; Historical for the pre-acquisition Nasdaq-era shareholder base, which is no longer current following the completed take-private transaction.
Sources
- XOMA Royalty Corporation – press release, “XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.,” 21 November 2025, investors.xoma.com
- U.S. Securities and Exchange Commission – LAVA Therapeutics N.V. Form 8-K and Schedule TO-T/A filings, CIK 0001840748, sec.gov
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Shay Capital LLC | 25% | Netherlands Chamber of Commerce (KvK) | |
| Gts Securities LLC | 2% | Netherlands Chamber of Commerce (KvK) | |
| Rangeley Capital, LLC | 1.6% | Netherlands Chamber of Commerce (KvK) | |
| Citadel Advisors Llc | 0.5% | Netherlands Chamber of Commerce (KvK) | |
| Royal Bank of Canada | 0.4% | Netherlands Chamber of Commerce (KvK) |
Officers
10
Directors and officers of LAVA Therapeutics N.V.
Per LAVA Therapeutics N.V.’s 2025 SEC proxy statement (Form DEF 14A, record date around March 2025), Stephen Hurly served as Executive Director and Chief Executive Officer, a role he had held since June 2019, and Kapil Dhingra served as Chairperson and Non-Executive Director; both were nominated for board terms extending to 2027. Company records on file separately list additional individuals in operational roles, but these could not be independently verified against the company’s own SEC filings within this review and are therefore omitted here rather than repeated unverified. Nationality and country of residence for the company’s officers are not disclosed in the SEC filings reviewed. Following LAVA Therapeutics N.V.’s statutory merger into LAVA Therapeutics New Topco B.V., completed 21 November 2025, the legal entity’s board mandates ended upon the entity ceasing to exist in its previous form; this overview reflects the last verified pre-merger board composition.
Recent officer changes
- All director appointments at LAVA Therapeutics N.V. ended upon completion of the company’s statutory merger into LAVA Therapeutics New Topco B.V., effective 21 November 2025 (source: XOMA Royalty Corporation closing announcement; SEC filings).
Data availability
Classification: Partial. SEC proxy filings confirm the Chief Executive Officer and Non-Executive Chairperson roles and appointment context ahead of the 2025 annual meeting; a complete, independently verified roster of all directors and officers at the point the merger completed was not available from the primary sources reviewed, and nationality or residence information is not disclosed.
Sources
- U.S. Securities and Exchange Commission – LAVA Therapeutics N.V. Form DEF 14A, CIK 0001840748, sec.gov
- XOMA Royalty Corporation – press release, “XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.,” 21 November 2025, investors.xoma.com
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
Group Structure
Group structure of LAVA Therapeutics N.V.
LAVA Therapeutics N.V. is not an independent company. On 3 August 2025, it entered into a transaction agreement with XOMA Royalty Corporation, a Nevada corporation listed on Nasdaq under ticker XOMA, providing for a Dutch statutory merger under Sections 2:309 et seq. of the Dutch Civil Code in which LAVA Therapeutics N.V. (the disappearing company) would merge into LAVA Therapeutics New Topco B.V. (the acquiring company), a Dutch private limited liability company (besloten vennootschap) incorporated as a direct wholly owned subsidiary of LAVA Therapeutics N.V. to effect the transaction. Following a tender offer that closed 20 November 2025 with approximately 91.1% of shares validly tendered, XOMA Royalty Corporation announced on 21 November 2025 that the merger had completed and that it had acquired 100% of the shares of LAVA’s successor entity, LAVA Therapeutics New Topco B.V. (KvK 98007424). LAVA’s shares were suspended from trading and delisted from Nasdaq shortly thereafter. Group information reviewed 18 September 2026.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| LAVA Therapeutics New Topco B.V. | NL | 98007424 | Successor entity following statutory merger | 100% (Class B shares) | Active | 21 Nov 2025 |
| XOMA Royalty Corporation | US | Nevada corporation (Nasdaq: XOMA) | Ultimate parent | 100% of LAVA’s successor entity | Active | 21 Nov 2025 |
Recent structural changes
- Transaction agreement signed with XOMA Royalty Corporation for cash acquisition plus contingent value right, 3 August 2025 (source: SEC Form 8-K).
- Tender offer closed with approximately 91.1% of shares tendered, 20 November 2025 (source: XOMA Royalty Corporation press release).
- Dutch statutory merger of LAVA Therapeutics N.V. into LAVA Therapeutics New Topco B.V. completed and transaction closed, making LAVA’s successor a wholly owned subsidiary of XOMA Royalty Corporation, 21 November 2025 (source: XOMA Royalty Corporation press release).
Data availability
Classification: Full. The transaction structure, closing date and resulting ownership are confirmed through SEC EDGAR filings (CIK 0001840748) and XOMA Royalty Corporation’s official investor relations announcements.
Sources
- U.S. Securities and Exchange Commission – LAVA Therapeutics N.V. Form 8-K exhibits and Schedule TO-T/A, CIK 0001840748, sec.gov
- XOMA Royalty Corporation – press release, “XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.,” 21 November 2025, investors.xoma.com
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
Ligand Pharmaceuticals Incorporated
United States
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does LAVA Therapeutics N.V. do?
LAVA Therapeutics N.V. (KvK 65335740) was a Utrecht, Netherlands-registered clinical-stage immuno-oncology company that developed bispecific gamma-delta T-cell engaging antibodies through its Gammabody platform, with partnered programmes involving Johnson & Johnson and Pfizer and an internal lead candidate, LAVA-1266.
Who owns LAVA Therapeutics N.V.?
As of 21 November 2025, XOMA Royalty Corporation (Nasdaq: XOMA) holds 100% of the shares of LAVA Therapeutics N.V.'s successor entity, following a tender offer in which approximately 91.1% of shares were validly tendered and a subsequent Dutch statutory merger; pre-acquisition Nasdaq-era shareholder records are no longer current.
Who is LAVA Therapeutics N.V.'s UBO (Ultimate Beneficial Owner)?
Every shareholder recorded for LAVA Therapeutics N.V. is itself a company rather than a natural person, so no Ultimate Beneficial Owner (UBO) is identified at this level; establishing one would require tracing the ownership of each shareholding company in turn.
What is LAVA Therapeutics N.V.'s company registration number?
LAVA Therapeutics N.V.'s registration number is 65335740, filed with Netherlands Chamber of Commerce (KvK) in Netherlands. Its current status on the register is inactive.
Is LAVA Therapeutics N.V. still an active company?
LAVA Therapeutics N.V.'s status on Netherlands Chamber of Commerce (KvK) is listed as inactive, not currently active.
When was LAVA Therapeutics N.V. incorporated?
LAVA Therapeutics N.V. was incorporated on 15 February 2016, according to Netherlands Chamber of Commerce (KvK).
What is LAVA Therapeutics N.V.'s registered address?
The registered address on file for LAVA Therapeutics N.V. is Utrecht, Netherlands.
Is LAVA Therapeutics N.V. listed on a stock exchange?
Previously listed on Nasdaq under ticker LVTX; trading was suspended and the company was delisted following completion of its acquisition by XOMA Royalty Corporation on 21 November 2025.
Who are the officers/directors of LAVA Therapeutics N.V.?
Per LAVA Therapeutics N.V.'s 2025 SEC proxy filing, Stephen Hurly served as Executive Director and CEO and Kapil Dhingra as Non-Executive Chairperson; all director appointments ended upon the company's statutory merger into LAVA Therapeutics New Topco B.V. on 21 November 2025.
Does LAVA Therapeutics N.V. have a parent company or subsidiaries?
LAVA Therapeutics N.V. merged, as the disappearing company, into LAVA Therapeutics New Topco B.V. (KvK 98007424) under a Dutch statutory merger completed 21 November 2025, making the successor entity a wholly owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA), a Nevada corporation.
Can Zavia monitor changes to LAVA Therapeutics N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Netherlands Chamber of Commerce (KvK). Zavia's monitoring API can track changes to LAVA Therapeutics N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access LAVA Therapeutics N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Netherlands, so records like LAVA Therapeutics N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Netherlands Chamber of Commerce (KvK) and was last synced on 18 September 2026.